[EN] AZASPIROCYCLES AS MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] AZASPIROCYCLES SERVANT DE MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2021191390A1
公开(公告)日:2021-09-30
Azaspirocycle compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R1, R2a, R2b, R3, m, n, o, and p are defined herein.
式(I)的Azaspirocycle化合物,以及其药学上可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体,含有它们的药物组合物,制备它们的方法,以及使用它们的方法,包括用于治疗与MGL调节相关的疾病状态、紊乱和症状的方法,例如与疼痛、精神紊乱、神经紊乱(包括但不限于重度抑郁症、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合症、双相情感障碍)、癌症和眼部疾病相关的方法:其中X、R1、R2a、R2b、R3、m、n、o和p在此处定义。